Our laboratory tests to date indicate that COR-101 also recognizes the particularly aggressive new Indian variant B1.617, which currently appears to supersede the English variant B.1.1.7.Dr. Andreas Herrmann, CEO, CORAT Therapeutics
On May 5th, 2021, the WHO classified the B.1.617 SARS-CoV-2 variants detected in India as “of concern”. According to current data from the European Centre for Disease Prevention and Control (ECDC), within a few weeks these variants in India have almost completely displaced previous SARS-CoV-2 variants, including the “British” variant B.1.1.7 currently prevalent in Germany. According to ECDC analysis, the mutations likely increase transmissibility and decrease neutralization by convalescent plasma and currently approved therapeutic antibodies, explaining the sharp increase in the number of cases in India in recent weeks. The currently used vaccines obviously have different efficacies against the newly emerging variants. Also, while vaccines can protect healthy people, they cannot cure people already suffering from COVID-19; moreover, not everyone responds to vaccination. For these patients CORAT Therapeutics is developing COR-101 that acts directly against the SARS-CoV-2 virus.